Diabetes Mellitus, Type 2

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Dallas, Texas, United States

• Kunisaki Makoto Clinic — Fukuoka, Fukuoka, Japan
• Seino I.M. Clinic, Fukushima, I.M. — Fukushima, Koriyama, Japan
• Nippon Kokan Fukuyama Hospital — Hiroshima, Fukuyama, Japan
• Nakakinen Clinic — Ibaraki, Naka, Japan

• Novo Nordisk Investigational Site — Berlin, Germany

Not specified

• Novo Nordisk Investigational Site — Huntsville, Alabama, United States
• Novo Nordisk Investigational Site — Vestavia Hills, Alabama, United States
• Novo Nordisk Investigational Site — Anaheim, California, United States
• Novo Nordisk Investigational Site — Los Angeles, California, United States

• Novo Nordisk Investigational Site — Birmingham, Alabama, United States
• Novo Nordisk Investigational Site — Goodyear, Arizona, United States
• Novo Nordisk Investigational Site — Mesa, Arizona, United States
• Novo Nordisk Investigational Site — Phoenix, Arizona, United States

• Novo Nordisk Investigational Site — Harrow, United Kingdom

• Center for Diabetes Research, Gentofte Hospital, University of Copenhagen — Hellerup, Denmark

• Novo Nordisk Investigational Site — Fresno, California, United States
• Novo Nordisk Investigational Site — Los Alamitos, California, United States
• Novo Nordisk Investigational Site — Palm Springs, California, United States
• Novo Nordisk Investigational Site — San Diego, California, United States

• CHU de Dijon — Dijon, France